Related StoriesMobile analysis device to help reduce unnecessary antibiotics prescribingNew generation of RNAscope items for RNA-biomarker evaluation in FFPE cells releasedEKF introduces particular biomarker test for early sepsis identificationVision of Shared Avoidance Trials Lures Pharma to Desk Can Alzheimer’s Avoidance Initiative Break a Catch-22? Trials in Colombia and the U.S. For Those at Highest Risk? For Shared Avoidance Trials, Devil Is in the facts Making Trials Function for Patient, Sponsor, Regulator See also a PDF of the entire series.. Alzheimer’s avoidance initiative: Shared risks and shared rewards The field is abuzz with the word prevention, but how exactly to accomplish this vaunted goal? It has been held back by a strange Capture-22 of cost, period, and biomarker validation.By continuing our support of the American Cardiovascular Association, we’re helping shed more light upon this preventable disease, and along the way, save the lives of more women. This season marks the sixth consecutive year that Dark brown & Toland Doctors has backed the American Heart Association. Â.. Antidepressant drug product sales plummet as patents expire and patients flee to safer alternatives The market for antidepressant drugs is quickly drying up as patents about long-time blockbusters like Lexapro, possessed by Forest Laboratories, and Seroquel, possessed by AstraZeneca, continue steadily to expire. And because they are unable to develop fresh multi-billion-dollar blockbuster medicines to take their locations, many drug producers are altogether ditching the antidepressant business, especially as studies continue steadily to emerge showing that antidepressants are largely worthless and cause more damage than good.